Procedure and assessments
Cancer
ADVERSE EVENT, DISEASE PROGRESSION, ADVERSE EVENTS, BLOOD, CANCER
This dose‐escalation trial employed a “Rolling 6” design,Blood samples were collected from each patient after a single dose of HS‐10352 on Day 1 of Cycle 0, followed by a 7‐day observation period. Repeated administration of the same dose commenced on Day 8, marking the beginning of Cycle 1. Each treatment cycle lasted for 4 weeks. Treatment with HS‐10352 would be discontinued in case of disease progression, adverse events (AEs), serious protocol violations, withdrawal of consent, or other circumstances as determined by the investigators or the sponsor.Treatment response was assessed by the investigators every 8 weeks according to RECIST v1.1. Patients were followed up for safety for 28 days after treatment discontinuation. Any AEs occurring during the trial were recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0,